



HALTON REGION PUBLIC HEALTH • Office of the Medical Officer of Health

TEL: 905-825-6000 • TOLL FREE: 1-866-442-5866 • FAX: 905-825-1444

TO: Halton Physicians, Nurse Practitioners, Emergency Departments, other Healthcare Providers

FROM: Dr. Joanna Oda, Associate Medical Officer of Health

DATE: October 15, 2024

RE: Nirsevimab (Beyfortus®), Influenza and COVID KP.2 Vaccines Available for Ordering

QUICK FACTS

- Nirsevimab (Beyfortus®) is now in stock at the Public Health Unit and is available for distribution to healthcare providers.
- Only the 100 mg dose is currently available. The 50 mg dose is expected to be available by the last week in October.
- To order Nirsevimab, please fill out the <u>Respiratory Syncytial Virus (RSV) Products Order Form</u> and fax it to 905-465-3403. Orders will be distributed according to the <u>vaccine distribution</u> schedule.
- South Halton facilities that would like to receive 100 mg doses of Beyfortus® before their next scheduled distribution date on October 29/30 may place their order by October 16th, for pick up only, at 1151 Bronte on October 23 from 9 a.m. to 1:30 p.m.
 - Only orders for 100 mg doses of Beyfortus® will be processed early.
 - o All other vaccine products will be distributed as per the usual vaccine distribution schedule.
- Starting Tuesday, October 15, both Pfizer and Moderna KP.2 COVID-19 and influenza vaccines
 will be available on the online <u>vaccine order form</u>. Please see the <u>Physician Update of September</u>
 30, 2024, for more details.

KEY MESSAGES FOR HEALTHCARE PROVIDERS

- Nirsevimab (Beyfortus®) is a monoclonal antibody that provides protection against severe RSV disease. It is recommended and publicly funded for:
 - All children born during the 2024-2025 RSV season
 - o All children born in 2024 prior to the RSV season
 - Children up to 24 months of age with any of the following conditions:
 - Chronic lung disease of prematurity, including bronchopulmonary dysplasia
 - Hemodynamically significant congenital heart disease
 - Severe immunodeficiency
 - Down Syndrome / Trisomy 21
 - Cystic fibrosis with respiratory involvement and /or growth delay
 - Neuromuscular disease impairing clearing of respiratory secretions
 - Severe congenital airway abnormalities impairing clearing of respiratory secretions
- Beyfortus® is available in 50 mg and 100 mg prefilled syringes

- Beyfortus® 100 mg is indicated for children weighing 5 kg or more.
- Beyfortus® 50 mg is indicated for infants under 5 kg.
- Do **not** split a 100 mg dose to create two 50 mg doses or reduce a 100 mg dose to withdraw a single 50 mg dose. Wait until the 50 mg formulation is available to begin administration to infants <5kg.
- Beyfortus® can be administered with routine childhood vaccines, as well as flu and COVID-19 vaccines.
 - Please consider using well-child visits or other opportunities this fall/winter to offer Beyfortus® to eligible patients.
 - Ask families with infants born during the RSV season this year if their baby received Beyfortus® in-hospital prior to discharge.
- When placing your order, ensure there will be adequate space in your vaccine fridge to store all quantities ordered. Pack dimensions for Beyfortus® are as follows:

Pack Quantity	Dimensions
1-pack, 50 mg and 100mg	144mm x 51mm x 24mm
5-pack, 100mg	140mm x 108mm x 24mm

ADDITIONAL RESOURCES

- Watch the Public Health webinar on RSV, COVID-19, Influenza, and Pneumococcal Updates (YouTube video) on September 25, 2024.
- Respiratory Syncytial Virus (RSV) Prevention Programs, Ministry of Health
- Beyfortus® (nirsevimab) Product Monograph
- Respiratory Viruses and Immunizations, Provincial Council for Maternal and Child Health
- RSV infants and high-risk children factsheet for healthcare providers
- Protecting your child from RSV parent factsheet

Please report all suspected/confirmed cases of <u>Diseases of Public Health Significance</u> (only report COVID-19 cases occurring in high-risk settings) to Public Health immediately by calling 311, 905-825-6000 or toll free at 1-866-442-5866.